Global Immunology Drugs Market Size Expected To Grow At A CAGR Of 8.2% to $113 Billion In 2023

Researchmoz added Most up-to-date research on "Global Immunology Drugs Market Size Expected To Grow At A CAGR Of 8.2% to $113 Billion In 2023" to its huge collection of research reports.

Global Immunology Drugs Market

Immune-mediated inflammatory diseases are a common set of chronic disorders that affect 5-7% of people in Western populations.

Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response.

This report covers all immunological disorders, but there is a particular focus on four key diseases, rheumatoid arthritis, psoriasis, inflammatory bowel disease and graft versus host disease/transplant rejection, as these conditions have the largest pipelines within the therapy area.

The market size for immunology therapeutics was valued at $65.1 billion in 2016 and it is expected to grow at a compound annual growth rate (CAGR) of 8.2% to $113 billion in 2023.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1769909

Scope

• The immunology market landscape is expected to change. Biosimilar competition is expected to affect the revenue of the big blockbuster drugs, and novel targets are expected to enter the market and drive market growth.
• Overall, there are 2,070 immunology products in the pipeline.
• Which molecular targets are most prominent within the pipeline?
• How do the key indications differ in terms of molecule type?
• How does the composition of the pipeline compare with that of the existing market?
• What mechanisms of action are most common for pipeline drugs?
• The market size for immunology therapeutics is expected to grow, from $65.1 billion in 2016 to $113 billion in 2023, at a CAGR of 8.2%.
• Which products will contribute to market growth most, and which will achieve blockbuster status?
• Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?
• What CAGR will these companies register in the forecast period?
• How many strategic consolidations have been completed in the past decade?
• Which types of assets attract the largest deal values?

Browse TOC @ https://www.researchmoz.us/global-immunology-drugs-market-to-2023-shifting-landscape-as-uptake-of-interleukin-receptor-inhibitors-offsets-losses-for-top-blockbuster-drugs-report.html/toc

Reasons to buy

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the four key indications.
• Visualize the composition of the immunology market overall and across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
• Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological conditions.
• Identify trends and developments, in terms of molecule type and molecular target, within the overall immunology pipeline, as well as for each of the four key indications.
• Understand the growth in patient epidemiology and market revenues for the dermatology market globally, and across the key players and product types.
• Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.
• Recognize how the evolving treatment landscape will drive market growth to 2023 and understand the contributions that different products, molecular targets and companies will make to this growth.
• Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals.

Global Immunology Drugs Market Forecast To Grow At A CAGR Of 3.63% During The Period 2015 - 2022

Researchmoz added Most up-to-date research on "Global Immunology Drugs Market Forecast To Grow At A CAGR Of 3.63% During The Period 2015 - 2022" to its huge collection of research reports.

Global Immunology Drugs Market

Immunology is a therapy area characterized by disorders of the immune system, specifically an aberrant autoimmune response against healthy tissues in the body, leading to chronic or acute inflammation. Depending on the specific site affected, this can lead to various types of chronic pain and mobility loss, and have a negative impact on quality of life.

A number of therapies have been approved for immunological disorders, including the largely genericized disease-modifying anti-rheumatic drug (DMARD) class of small molecule drugs. However, as these therapies often fail to elicit an adequate long-term response, a large second-line therapy segment has emerged in these markets, beginning with the approval of Remicade (infliximab) and Enbrel (etanercept) in 1998. There is currently no cure for immunological disorders due to the highly complex nature of the immune system and the fact that many components of the pathophysiological states of these diseases have roles in the healthy immune system.

Autoimmune disorders are currently incurable, and treatment is aimed at managing the disease, in order to reduce the severity of its symptoms and lower the risk of associated co-morbidities. Cytokines and their receptors, such as Tumor Necrosis Factor-? and Interleukin-6 are the most effective and most common therapies used in immunology. This class of compounds has been the most commercially successful in the past decade, particularly in the RA market, with many clinical trials underway across various immunological indications. The market for immunological disorders is largely accounted for by premium products, with only a relatively small revenue share accounted for by generics and biosimilars.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1160848

Inflectra, a biosimilar of Remicade was recently approved by the FDA in 2016. However, the gradual uptake of biosimilars such as Inflectra is not expected to act as a strong growth driver for the biosimilar segment within the forecast period. This therefore means existing products such as Remicade are expected to maintain high revenues during the forecast period

Although there is a high degree of failure and uncertainty in R&D of immunological drugs, there are 2,054 drugs in active development in the immunology pipeline. In the long-term, this is expected to drive growth in this market in spite of the anticipated approval of biosimilars for key blockbuster drugs and resultant erosion of revenues. Cytokines and their receptors account for the largest single segment of each of the pipelines which make up the largest individual class.

The report focuses on four key indications within immunology: Rheumatoid arthritis, Systemic lupus erythematosus (SLE), Psoriasis and Inflammatory bowel disease (The two major types of Inflammatory bowel disease covered in this report are Ulcerative colitis and Crohn’s disease). With no curative therapies available, symptomatic medications prescribed off-label are an important part of the treatment paradigm, especially in SLE, increasing the need for extensive R&D within this area.

Scope

• Global revenues for the immunology market are forecast to grow at a compound annual growth rate of 3.63%, from $57.7 billion in 2015 to $74.1 billion in 2022.
• Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
• The immunological disorders pipeline is large and diverse, and contains 2,054 products. How does the composition of the pipeline compare with that of the existing market?
• What molecular targets and molecule types are most commonly being trialed in pipeline products in the key indications?
• Which products will contribute to market growth most significantly, and which will achieve blockbuster status?
• Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the immunology market set to change?

Browse TOC @ https://www.researchmoz.us/global-immunology-drugs-market-to-2022-increasing-prevalence-repositioning-opportunities-and-strong-uptake-of-interleukin-receptor-inhibitors-to-drive-growth-report.html/toc

Reasons to buy

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
• Visualize the composition of the immunology market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
• Analyze the immunological disorders pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
• Understand the growth in patient epidemiology and market revenues for the immunology market, globally and across the key players and product types
• Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various immunological disorders.
• Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals

Global Immunology Drugs Market Expected To Grow At A CAGR Of 8.2% To $113 Billion In 2023

Researchmoz added Most up-to-date research on "Global Immunology Drugs Market Expected To Grow At A CAGR Of 8.2% To $113 Billion In 2023" to its huge collection of research reports.

Global Immunology Drugs Market

Immune-mediated inflammatory diseases are a common set of chronic disorders that affect 5-7% of people in Western populations.

Although they are often disparate in terms of their symptoms and key patient demographics, they are pathophysiologically linked, being characterized by dysregulation of immune pathways and an inappropriate immune response.

This report covers all immunological disorders, but there is a particular focus on four key diseases, rheumatoid arthritis, psoriasis, inflammatory bowel disease and graft versus host disease/transplant rejection, as these conditions have the largest pipelines within the therapy area.

The market size for immunology therapeutics was valued at $65.1 billion in 2016 and it is expected to grow at a compound annual growth rate (CAGR) of 8.2% to $113 billion in 2023.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1769909

Scope

• The immunology market landscape is expected to change. Biosimilar competition is expected to affect the revenue of the big blockbuster drugs, and novel targets are expected to enter the market and drive market growth.
• Overall, there are 2,070 immunology products in the pipeline.
• Which molecular targets are most prominent within the pipeline?
• How do the key indications differ in terms of molecule type?
• How does the composition of the pipeline compare with that of the existing market?
• What mechanisms of action are most common for pipeline drugs?
• The market size for immunology therapeutics is expected to grow, from $65.1 billion in 2016 to $113 billion in 2023, at a CAGR of 8.2%.
• Which products will contribute to market growth most, and which will achieve blockbuster status?
• Will the current market leaders retain their dominance over the forecast period, and how is their revenue share of the dermatology market set to change?
• What CAGR will these companies register in the forecast period?
• How many strategic consolidations have been completed in the past decade?
• Which types of assets attract the largest deal values?

Browse TOC @ https://www.researchmoz.us/global-immunology-drugs-market-to-2023-shifting-landscape-as-uptake-of-interleukin-receptor-inhibitors-offsets-losses-for-top-blockbuster-drugs-report.html/toc

Reasons to buy

• Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis for the four key indications.
• Visualize the composition of the immunology market overall and across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players.
• Stratify the market in terms of the split between generic and premium products and assess the role of these product types in the treatment of the various immunological conditions.
• Identify trends and developments, in terms of molecule type and molecular target, within the overall immunology pipeline, as well as for each of the four key indications.
• Understand the growth in patient epidemiology and market revenues for the dermatology market globally, and across the key players and product types.
• Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates, by stage of development, key indication, molecule type and molecular target.
• Recognize how the evolving treatment landscape will drive market growth to 2023 and understand the contributions that different products, molecular targets and companies will make to this growth.
• Identify commercial opportunities in the immunology deals landscape by analyzing trends in licensing and co-development deals.